Global innovative drug sales map

In a flash, almost a quarter of 2022 has passed, and the 2021 financial reports of global pharmaceutical giants have been released one after another
.

Focusing on the global innovative drug market, two major events have affected the hearts of innovative drug investors.

But no matter how many bright moments an innovative drug has gone through in research and development, a core factor that ultimately judges the success of a drug is always the sales of the drug

0 1 ADC drug

In 2021, the market size of the global ADC field will exceed US$5 billion , and T-DM1 (Kadcyla) will still dominate the pack with sales of US$2.
178 billion
.

But it is not difficult to find from the form that there are only two ADC drugs with sales exceeding $1 billion, namely Kadcyla and Adcetris

In 2021, the market size of the global ADC field will exceed US$5 billion

It has to be said that although the efficacy data of DS-8201 has obvious advantages over T-DM1, for innovative drugs, the market advantage brought by the first-mover advantage is too obvious
.

Of course, the market advantage brought by the first-mover advantage gradually weakens with the launch of high-quality competing products.

In response, T-DM1 took advantage of the price war to speed up its market share
.

Recently, T-DM1 has taken the initiative to reduce the price by more than 50% in China.

Of course, in addition to the above three ADC drugs, the market sales of other ADC products are far from satisfactory
.

From the perspective of tumors, the sales of solid tumor targets are still remarkable.

Of course, in addition to the above three ADC drugs, the market sales of other ADC products are far from satisfactory

Data source: corporate financial report

0 2 CAR-T products

0 2 CAR-T products

In 2021, the global CAR-T market will reach USD 1.
7 billion
.

Kymriah and Yescarta, as two "veteran" products in the CAR-T field, are experiencing a significant slowdown in growth rate

The competition in the BCMA CAR-T field is much milder, with Abecma achieving $164 million in sales in its first year on the market
.

In terms of efficacy, Legend Bio/Johnson & Johnson's Carvykti far outperforms Abecma with an objective remission rate of 97.

The future space geometry of CAR-T products is difficult to determine
.
However, the problems of cost and benefit here are always thought-provoking.
In 2017, Gilead Sciences acquired Kite Pharma for $11.
9 billion, and as of the end of 2021, Yescarta and Tecartus have achieved a cumulative revenue of $2.
154 billion, which is far from cost recovery.
Still a long way off
.

Figure: List of CAR-T product sales in 2021

Data source: corporate financial report

0 3 Double Antibody Products

0 3 Double Antibody Products

In the field of double antibodies, Johnson & Johnson's Rybrevant targeting EGFR × cMet will be approved for marketing in 2021, and the FDA will approve the marketing application of Genentech's Vabysmo (VEGF-A × Ang-2) in January 2022
.
Amgen's Blincyto achieved sales of $472 million, up 24% year over year
.
However, in the field of double antibodies, Hemlibra topped the list with sales of up to 3.
5 billion US dollars.
scope of use
.

Chart: List of Double Antibody Drug Sales in 2021

Data source: corporate financial report

0 4Summary _

0 4Summary _

In recent years, although the research and development of ADC, double antibody, and CAR-T track is in the ascendant, and a large number of companies are deeply engaged in these new fields, from the perspective of the market, except for Hemlibra, Kadcyla and Adcetris, the sales of other drugs have not exceeded 10%.
billion dollars
.
Although the market prospect of tumor is extremely broad, behind the fiery research and development, the real return of the company is embarrassing
.
The returns in the CAR-T field even illustrate some problems.
Kymriah and Yescarta have been on the market for nearly five years, but the $700 million in sales is still a certain distance from a blockbuster
.

The reason is that although these innovative drugs represent the forefront of scientific and technological progress, their high safety risks make it difficult for them to challenge the front-line therapy of tumor treatment.
In addition, the high price also limits the popularization of drugs, so the first-line therapy is still It is a treatment plan represented by traditional monoclonal antibodies and small molecule drugs
.
Looking back at the TOP10 list of the world's best-selling anti-tumor drugs in 2021, K drug, lenalidomide, and ibrutinib are still three-legged, while ADC, double antibody and CAR-T therapy are still not on the list
.
In the future, we hope that more innovative drugs with both efficacy and safety will be launched, which will not only represent the forefront of research and development, but also bring good profits to enterprises
.

Although these innovative drugs represent the forefront of scientific and technological progress, their high safety risks make it difficult for them to challenge the front-line therapy of tumor treatment.
In addition, the high price also limits the popularization of drugs, so the first-line therapy is still based on traditional single therapy.
Treatment options represented by anti- and small-molecule drugs
.

Figure: TOP 10 of the world's best-selling anti-tumor drugs in 2021

Data source: Biospace

Note: Click on the picture to read the related article "Top 10 Global Sales of Anticancer Drugs in 2021: Roche Accounts for Half, and K Drugs Exceed $17.
1 Billion"